TREM2 and Alzheimer disease: In addition, Denali Therapeutics and Takeda have partnered to develop an antibody called DNL919 (ATV: TREM2), which is designed to activate the TREM2 receptor through intravenous administration to improve TREM2 function for therapeutic use in AD.